Cytosorbents Corp

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

CTSO$5.80-0.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss


· · Year ended · · Year ended
· · December 31, · · December 31,
· 2024 · 2023
· · As restated
Product revenue	$35,594,520	$31,084,953
Cost of goods sold	10,468,529	9,131,716
Gross profit	25,125,991	21,953,237
Operating expenses:
Research and development, net of grant income	6,916,181	15,594,442
Selling, general and administrative	34,995,749	38,307,415
Total operating expenses	41,911,930	53,901,857
Loss from operations	(16,785,939)	(31,948,620)
Other income (expense):
Interest expense, net	(1,399,092)	(157,891)
Gain (loss) on foreign currency transactions	(4,224,721)	1,949,257
Miscellaneous income (expense)	(30)	96,755
Total other income (expense), net	(5,623,843)	1,888,121

Loss before benefit from income taxes	(22,409,782)	(30,060,499)

Benefit from income taxes	1,690,825	813,739

Net loss attributable to common stockholders	$(20,718,957)	$(29,246,760)

Basic and diluted net loss per common share	$(0.38)	$(0.65)

Weighted average number of shares of common stock outstanding	54,434,609	44,656,391

Comprehensive loss:
Net loss	$(20,718,957)	$(29,246,760)
Other comprehensive income (loss):
Foreign currency translation adjustment	4,027,003	(1,799,874)
Comprehensive loss	$(16,691,953)	$(31,046,634)

CONSOLIDATED STATEMENTS OF CHANGES IN

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.